Curis tumbles on FDA partial study hold after patient death
This article was originally published in Scrip
Executive Summary
Shares of Curis plunged 27% on 6 November on the company's revelation the US FDA had placed a partial clinical hold on a Phase I trial of CUDC-427, a small molecule antagonist of oral inhibitor of apoptosis proteins, after a patient who had been administered the experimental drug died.